In vivo protection from emerging SARS-CoV-2 variants by protein nanoparticle vaccine

863722

Sumary of In vivo protection from emerging SARS-CoV-2 variants by protein nanoparticle vaccine:

  • Researchers in the United States have developed a new coronavirus disease 2019 (COVID-19) vaccine that induced potent neutralizing antibodies against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in animal models..
  • The team developed a recombinant SARS-CoV-2 spike protein antigen containing mutations from the B.1.351 variant (Beta) that emerged in South Africa..
  • in Gaithersburg, Maryland, have shown that a recombinant spike protein (rS) antigen contains B.1.351 mutations (rS-B.1.351) protected mice against infection with B.1.351..
  • The vaccine also protected the animals against the B.1.1.7 variant that emerged in the UK and the original SARS-CoV-2 strain identified in Wuhan (Wuhan-Hu-1 strain)..
  • Furthermore, a robust anamnestic response was observed among baboons that were boosted with rS-B.1.351 approximately one year following immunization with a prototype vaccine the team previously developed that was based on the Wuhan-Hu-1 strain..
  • James Logue and colleagues say this points to the feasibility of using the vaccine as a booster following previous immunization with vaccines developed against the ancestral SARS-CoV-2 spike protein..
  • As a result of the continued global spread of SARS-CoV-2, several variant strains containing mutations have emerged, increasing transmissibility and conferring resistance to vaccination and infection..
  • While the B.1.1.7 variant )Alpha) is more transmissible compared with ancestral strains and has caused more hospitalizations globally, it is still effectively targeted by vaccine or infection-induced immunity and currently authorized monoclonal antibodies….

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close